A tuberculosis ontology for host systems biology  by Levine, David M. et al.
lable at ScienceDirect
Tuberculosis 95 (2015) 570e574Contents lists avaiTuberculosis
journal homepage: http: / / int l .e lsevierhealth.com/journals / tubeIMMUNOLOGICAL ASPECTSA tuberculosis ontology for host systems biology
David M. Levine a, Noton K. Dutta b, Josh Eckels c, Charles Scanga d, Catherine Stein e,
Smriti Mehra f, g, Deepak Kaushal g, Petros C. Karakousis b, Hugh Salamon h, *
a Department of Biostatistics, University of Washington, School of Public Health, Seattle, WA, USA
b Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
c LabKey Corporation, Seattle, WA, USA
d Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA
e Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA
f Department of Pathobiological Sciences, Louisiana State University School of Medicine, Baton Rouge, LA, USA
g Tulane National Primate Research Center, Covington, LA, USA
h Knowledge Synthesis Inc., Berkeley, CA, USAa r t i c l e i n f o
Article history:
Received 30 August 2014
Received in revised form
19 May 2015
Accepted 24 May 2015
Keywords:
Mycobacterium
Gene expression
Transcriptomics
Ontology
GEO* Corresponding author. Knowledge Synthesis, 725
94710, USA. Tel.: þ1 510 220 3122.
E-mail address: hugh@knowledgesynthesis.com (H
http://dx.doi.org/10.1016/j.tube.2015.05.012
1472-9792/© 2015 The Authors. Published by Elseviers u m m a r y
A major hurdle facing tuberculosis (TB) investigators who want to utilize a rapidly growing body of data
from both systems biology approaches and omics technologies is the lack of a standard vocabulary for
data annotation and reporting. Lacking a means to readily compare samples from different research
groups, a signiﬁcant quantity of potentially informative data is largely ignored by researchers. To facil-
itate standardizing data across studies, a simple ontology of TB terms was developed to provide a
common vocabulary for annotating data sets. New terminology was developed to address animal models
and experimental systems, and existing clinically focused terminology was modiﬁed and adapted. This
ontology can be used to annotate host TB data in public databases and collaborations, thereby stan-
dardizing database searches and allowing researchers to more easily compare results. To demonstrate
the utility of a standard TB ontology for host systems biology, a web application was developed to
annotate and compare human and animal model gene expression data sets.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is a major global health concern, responsible
for nearly 1.3 million deaths a year [1]. It is estimated that over one
third of the world's population has been infected with Mycobac-
terium tuberculosis [1]. The majority of those infections will remain
latent, but an estimated 5e10% of those who are not co-infected
with HIV will progress to active TB. Those who are co-infected
with HIV have much higher rates (up to 10% annually) of devel-
oping active TB than non-HIV infected persons.
Increasingly, researchers studying TB are using systems biology
approaches and omics technologies in their research. These ap-
proaches typically generate large genomic, transcriptomic or pro-
teomic data sets from mycobacteria, host animal models or human
samples and seek to identify signaling networks, metabolicFolger Avenue, Berkeley, CA
. Salamon).
Ltd. This is an open access article upathways, and genetic programs associated with active TB. Pres-
ently, a large quantity of data is being generated by the National
Institute of Allergy and Infectious Diseases (NIAID) systems biology
program [2] to characterize and study Mycobacterium tuberculosis
(Mtb). Here, we are particularly interested in mechanisms of TB
latency and reactivation in the host.
A major hurdle facing researchers who want to compare, inte-
grate and evaluate omics data is the lack of a standard vocabulary
for data annotation and reporting. This makes comparison of re-
sults from different research groups challenging due to the het-
erogeneity inherent in TB research, including differences in stage of
disease, host organism, tissue assayed, treatments, measurement
platforms, vaccination status, etc.
To address these issues we developed a simple ontology of TB
terms that provides a common vocabulary to annotate both clinical
and experimental data sets in a standardized manner. Our goal is to
provide a uniﬁed view of data sets and experiments in order to
facilitate data integration and promote collaboration among TB
research groups. We developed terminology to address animalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clinically focused terminology previously developed by the Clinical
Data Interchange Standards Consortium (CDISC [3]) and CPATH [4]
consortiums. We envision this ontology being used to annotate
host TB data in public databases (e.g., GEO [5]) and harmonize
multiple data sets for comparison.
2. TB ontology
The development of a TB ontology was motivated by our
participation in the National Heart, Lung, and Blood Institute
(NHLBI) “Systems Biology Approach to the Mechanisms of TB La-
tency and Reactivation” (TBSB) project [6]. TBSB is a collaboration of
ﬁve NHLBI-sponsored research centers and one data coordinating
center working to advance the scientiﬁc understanding of the
regulatory andmetabolic networks of TB latency and reactivation in
the host. Each research center studies latency in the host using
human subjects and/or various experimental systems, e.g., the
traditional BALB/c and the new C3HeB/FeJ mouse models, rabbits,
and cynomolgus and rhesus macaque models. Several different
omics technologies were employed to measure the host environ-
ment. Our goals were to develop an ontology that would encourage
data integration within the TBSB project, leverage the growing
body of public domain TB data, and compare our animal models
with human subjects.
A draft ontology for TB clinical data had already been developed
by CDISC. They generated a set of terms and their deﬁnitions related
to TB diagnosis and treatment based on usage in various TB data-
bases and from several TB studies. This work was later completed
under the Critical Path to TB Drug Regimens (CPTR) initiative [4]
and led to the recent release of a Tuberculosis User Guide [3] for
guiding the organization, structure, and format of standard tuber-
culosis clinical trial datasets submitted to the FDA.
To develop our ontology, we used the structure of the CDISC
ontology and a subset of 40 of their 139 terms and deﬁnitions as the
backbone for our work. When appropriate, we modiﬁed and/or
extended their work and also added 30 additional terms and def-
initions to cover experimental systems and omics technologies and
organized these categorically. For example, we modiﬁed the
permissible values for the term “Interferon Gamma Release Assay”
to include assays for nonhuman primates (NHPs). We also lever-
aged existing deﬁnitions for race and ethnicity created by the US
Center for Disease Control and Prevention [7] (CDC), a list of
countries of origin from Wikipedia [8], and a standardized list of
codes for identifying the assay platform from the GEO project [5].
The ontology contains 70 terms binned into 12 categories. Each
term consists of the name of the term, the category to which it
belongs, its deﬁnition, and a list of permissible values for that term.
Where possible, the list of permissible values is selected from a
controlled vocabulary, although for some terms we considered it
necessary to include an “Other” option to accommodate a likely
need for extension. Table 1 contains examples of terms from several
different categories of the TB ontology. Table 2 contains a list of
categories and a count of the number of terms in each category. The
complete ontology is available as Supplementary Data and from the
TBSB web site [9].
3. Implementation of the TB ontology
To demonstrate the utility of the TB ontology we developed a
web-based application using LabKey Server [10] that stores,
queries, normalizes and reports on gene expression data. We chose
to focus on gene expression data because it is the most common
type of omics data, both in the public domain and in the TBSB
consortium. However, there is nothing inherent in either the TBontology or our implementation that prevents integrating and
comparing other omics data types.
Three types of data are required for inclusion of a data set in our
application. First, a matrix of numerical values is needed for the
features measured by the platform in each sample. For microarray
data, our implementation supports both single channel intensity
and two channel ratio data, either optionally log-transformed. We
focused on high-level gene expression data since there are many
options for low-level preprocessing and normalization [11], after
which any gene expression data set can be viewed as a similar
sample-by-feature rectangular matrix. Also, for data sets down-
loaded fromGEO, we preferred to rely on the normalization choices
of the researchers who ran the original experiments, rather than
renormalize the data ourselves.
Second, annotations are needed for the platform to identify the
genes or proteins being assayed. The annotations we included are
the gene symbol, probe identiﬁer and, when available, the UniGene,
Entrez, RefSeq and accession number NCBI identiﬁers. Most
microarray vendors provide a manifest, which maps the probe/
features on their platform to these annotations.
Lastly, each sample needs to be annotated in an informativeway.
It is the role of the TB ontology to facilitate this. Ideally, these an-
notations would be provided by the original researchers. For data
sets retrieved from GEO [5], some of the sample annotations are
provided in the Minimum Information about a Microarray Experi-
ment [12] (MIAME) annotations which are a part of data sets
uploaded into GEO. All other annotations were provided by the
authors.
In general, due to platform and batch effects [13], it is not
reasonable to normalize data sets between microarray studies,
even on the same platform. Instead, transcript measurements from
a sample(s) should only be interpreted in the context of other
samples in that data set. Therefore, when comparing multiple data
sets we selected a set of samples to use as a baseline and a second
set of comparator samples, each of which is compared, on a probe-
by-probe basis, to the mean of the baseline samples. The result is
the fold change of each sample in the comparison group relative to
the baseline mean.
We developed a web-based graphical user interface (GUI),
implemented using LabKey Server's back-end database that re-
trieves subsets of the data deﬁned by queries using the TB ontology
for sample selection and gene identiﬁers for probe selection. The
GUI is shown in Figure 1. Multiple data sets can be queried simul-
taneously using the same or different TB ontology terms. The query
is processed by LabKey Server and submitted to the backend
database. The selected data is returned and processed by a customR
[14] function we wrote and integrated into the LabKey system.
The R function takes the antilog of any logged data, computes
the mean of the baseline samples in each data set, and scales the
comparator samples by the baseline mean to compute the fold
change of each comparator group sample relative to the baseline
mean. To visualize the results we developed a side-by-side boxplot
comparison of the expression of the baseline set of samples and the
comparator set of samples for each data set. We use a Wilcoxon
rank-sum test to compare the two groups. An example of the
output is shown in Figure 2 in the next section.
4. Example
To demonstrate the utility of the TB ontology we used it to
annotate four gene expression data sets (Table 3). Two of these are
human data sets from the public domain [15,16]. The other two are
animal models (mouse [17] and rhesus [18]) from the TBSB project.
We selected samples from each data set using the TB ontology and
genes via their gene symbol.
Table 1
Exemplary terms used in the TB ontology.
Category Term Deﬁnition Permissible values
Clinical and physical
identiﬁcation
Interpretation of
tuberculin skin test (TST)
Outcome of the tuberculin skin test result,
based on the number of millimeters and
international guidelines.
Positive; negative; unknown; unable to determine
Coinfection HIV status The state of being HIV-positive or HIV-negative. Positive (self reported); negative (self reported);
positive (test result available); negative
(test result available); unable to determine;
test done, results unknown; test not done
Disease condition Identiﬁcation of subject
tuberculosis status
Identiﬁcation of subject's status Suspected case of active tuberculosis; conﬁrmed
case of active tuberculosis; latent tuberculosis;
contact of case of tuberculosis; no tuberculosis;
prior history of active TB; work up in progress
Disease condition Latent tuberculosis
infection status
Current status of latent tuberculosis infection Yes; no; unknown
Disease condition Relapsed Relapsed tuberculosis infection Yes; no
Experimental or clinical
system organisms
Mycobacterium species The type of mycobacterium isolated or otherwise
identiﬁed in a clinical specimen.
M. tuberculosis; M. bovis; M. africanum; M. canettii;
M. microti; M. bovis BCG; M. bovis; M. avium
complex; M. kansasii; Other (specify)
Experimental or clinical
system organisms
Mycobacterium strain The strain of M. tuberculosis used. CDC1551; H37Rv; H37Ra; HN878; Erdman;
other (specify)
Experimental or clinical
system organisms
Detailed ethnicity CDC
concept code
CDC deﬁnition <ethnicity_codes-2.16.840.1.113883.6.238-10.31.08.txt:
Concept Code>
Experimental or clinical
system organisms
Detailed ethnicity CDC
preferred concept name
CDC deﬁnition <ethnicity_codes-2.16.840.1.113883.6.238-10.31.08.txt:
Preferred Concept Name>
Experimental or clinical
system organisms
Host species Species of host or cells from which bacteria were
isolated or in which bacteria or
symptoms detected.
Valid species name; free text
Experimental samples
and techniques
Sample component measured biochemical component of the sample that
was measured
DNA; mRNA; miRNA; protein; metabolite;
other (specify)
Experimental samples
and techniques
Assay technology Type of assay used to measure sample component GWAS; sequencing; microarray; RT-PCR; RNA-SEQ;
mass spectrometry; ﬂow cytometry; bead chip
Experimental samples
and techniques
Assay vendor Vendor of assay Free text
Experimental samples
and techniques
Assay platform Vendor platform <platforms.txt:Accession>
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status (Latent tuberculosis infection status), clinical outcome
(Tuberculosis Disease Outcomes Clinical), tissue type (Host Sample
Tissue), and organism (Host Species) to select latent and active TB
samples for comparison. The results of the query for an example
gene SERPINF1 (Serpin F1; also known as pigment epithelium-
derived factor, PEDF), are shown in Figure 2. Each column corre-
sponds to a probe for the gene SERPINF1 in one of the data sets.
Within a column, the boxplot labeled “baseline” shows the
expression of each latent TB sample in that data set and the
“comparison” boxplot shows the expression of each active TB
sample.
SERPINF1 is a multifunctional secreted protein with anti-
angiogenic, anti-tumorigenic, and neurotrophic functions. TheTable 2
Categories used in the TB ontology and the number of terms in each.
Category Number
Treatment 12
Disease condition 10
Experimental samples and techniques 10
Identiﬁcation 7
Experimental or clinical system organization 8
Clinical and physical identiﬁcation 5
Imaging 4
Experimental infection 3
Media 3
Coinfection 2
AFB staining 2
Immunization 1
Total 67results in Figure 2 show SERPINF1 is up-regulated in untreated
active TB relative to latent TB in both humans and animal models
and down-regulated after treatment (data set GSE11199). Tissue
hypoxia leads to the downregulation of SERPINF1 [19], perhaps
thereby promoting formation of new blood vessels. We have found
that TNF neutralization-induced reactivation of latent TB infection
in mice was associated with increased oxygen tension in lung le-
sions, and reduced expression of the pro-angiogenic vascular
endothelial growth factor (VEGF) [17]. Although the expression of
SERPINF1 has not been studied directly in TB granulomas of latently
infected humans or animals, we hypothesize that the tissue hyp-
oxia prevalent in such necrotic lesions would inhibit SERPINF1
expression. Conversely, TB reactivation, which is associated with
dissolution of granulomas and greater diffusion of oxygen across
such lesions, would be predicted to favor induction of SERPINF1
expression.5. Discussion
We developed an ontology of TB terms for use in annotating
clinical and experimental data sets. Ourmotivationwas to provide a
standardized, commonly accepted vocabulary to describe TB data.
An important goal was to be able to annotate data sets that are
assayed with omics technologies and used for systems biology
analysis. Many such data sets are already in the public domain [5]
and more may be expected as the popularity of new omics tech-
nologies such as RNA-Seq increases.
Many biomedical ontologies exist [such as bio-
portal.bioontology.org]. However, the detail provided in a disease-
speciﬁc ontology such as ours may get lost in larger ontologies that
Figure 1. Graphical user interface (GUI) for TB sample selection. The left side of the GUI implements the TB ontology using a tree view of the categories and terms within those
categories. The user chooses the TB ontology terms and corresponding permissible values to combine with a Boolean AND to select the baseline and comparator samples,
respectively. The box at the bottom of the GUI is used to specify one or more gene identiﬁers to measure in the selected samples. Here, samples are being selected from the Tulane
rhesus data set based on their “Latent Tuberculosis Infection Status”; “Yes” for baseline samples and “No” for comparison samples.
Figure 2. Expression level comparison. Each column corresponds to a probe for the gene SERPINF1 in one of the four data sets. The JHU data set has two such probes. The boxplots
within a column show the normalized expression of the baseline (latent TB) and comparator samples (active TB) selected using the TB ontology. The short red horizontal lines in
each boxplot indicate the mean expression level. The baseline mean is scaled to one within each data set. The asterisk in the GSE11199 data set indicates a statistically signiﬁcant
difference between the expression levels of the baseline and comparator groups.
Table 3
Four gene expression data sets used in example comparison.
Data set Host
organism
Tissue Active
TB
Latent
TB
Platform
GSE11199 Homo
sapiens
Monocyte
derived
macrophage
8* 7 Affymetrix HG-U133
GSE19439 Homo
sapiens
Blood 13 17 Illumina HumanHT-
12V3_0_R3_11283641_A
JHU Mus
musculus
Lung 3 3 Illumina MouseWG-6 v2.0
Expression BeadChip array
Tulane Macaca
mulatta
Lung 14 15 Agilent
* Treated and recovered.
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between the TB Ontology and the Ontology for Biomedical In-
vestigations (OBI), such as the term Cell Line, but other terms, such
as Latent Tuberculosis Infection Status, are not found in OBI. We
believe that the tuberculosis research-speciﬁc terms in TB Ontology
are needed to facilitate data sharing across the tuberculosis
research community. An important future step would be to provide
TB Ontology in Resource Description Framework (RDF) to facilitate
its comparison and linking with other ontologies such as OBI and
the Infectious Disease Ontology.
To demonstrate the utility of a standardized TB ontology, we
built a web application that leveraged the ontology to annotate and
compare human and animal model gene expression data sets. Even
with just four data sets, the heterogeneity was quite wide-spread;
D.M. Levine et al. / Tuberculosis 95 (2015) 570e574574and included data across different species, tissues, sample treat-
ments, assay platforms, and data transformations and normaliza-
tions. Nevertheless, the application allowed us to harmonize data
from the TBSB systems biology project with public domain data and
study the question of how well the different experimental model
systemsmirror the progression of the human infection and disease.
Beneﬁts of this ontology are uniform deﬁnitions that enable
standardized TB database searches, a methodology to harmonize
and compare results with those of other investigators, and a general
organizational framework for thinking about TB experiments. We
are hopeful that others will use this ontology to annotate their TB
data sets and upload them to public databases. Additionally, we
hope this TB Ontology will facilitate new collaborations.
This work has provided a template for how to use the TB
ontology to annotate a data set and how to harmonize and integrate
annotated public domain data with ongoing research. Although we
used gene expression data in our example, there is nothing in the
TB ontology or implementation that prohibits the storage of any
assay technology for which results can be summarized in the form
of a sample-by-feature matrix with each value being a measure-
ment level or ratio.
Availability and URLs
The TB Ontology web page https://tbsystemsbiology.org/wiki/
Public/page.view?name¼TB_Ontology contains links to the latest
version of the TB Ontology, the LabKey web application and all
associated data ﬁles.
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